Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis

ABSTRACT

Background

Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA). This study aimed to systematically evaluate the efficacy and safety of bimekizumab in the management of PsA.

Research design and methods

A comprehensive literature search by August 2023 was performed through PubMed, Embase, Cochrane Controlled Register of Trials, and ClinicalTrials.gov. investigating the efficacy or safety data of bimekizumab in the treatment of PsA. Data was pooled using the random-effects models. Egger tests were used to evaluate potential publication bias.

Results

A total of 4 RCTs, involving 892 PsA patients and 467 placebo controls, were included in this analysis. Bimekizumab significantly increased the rates of PASI75 and PASI100 compared with placebos [RR = 7.22, 95% CI (5.24, 9.94), p < 0.001; RR = 10.12, 95% CI (6.00, 17.09), p < 0.001]. The rate of overall adverse events was slightly higher in the bimekizumab group [RR = 1.42, 95% CI (1.05, 1.93) p = 0.023). However, there were fewer adverse severe drug reactions in the bimekizumab group compared to the placebo.

Conclusion

Bimekizumab had a significant clinical benefit in managing PsA and an acceptable safety profile.

KEYWORDS:

• Bimekizumab
• IL-17
• meta-analysis
• psoriatic arthritis
• biologic therapy

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

QY Su and L Yang designed the study. TY Cao, HY Dang, ZC Han, T Cheng, and HY Zhang searched the literature. QY Su, L Yang and JJ Cao extracted the data. HY Dang, ZC Han and JJ Cao analyzed the data. QY Su, L Yang and TY Cao wrote the manuscript. SX Zhang and YH Huo contributed to manuscript revision, read, and approved the submitted version. Both SX Zhang and YH Huo served as corresponding authors.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14740338.2024.2343017

Additional information

Funding

This work was supported by the National Science Foundation of China [No.82001740] and the Natural Science Foundation of Shanxi Province [No. 202203021221269].